Marriaga NB, López LP, Solórzano SF, Arellano-Valdez CA, Pacheco-Quintanares L, González Novoa DM

Idioma: Español
Referencias bibliográficas: 25
Paginas: 128-131
Archivo PDF: 173.66 Kb.

RESUMEN

La enfermedad de Behçet es una enfermedad inflamatoria sistémica, que se manifiesta clásicamente por la tríada de aftas orales, úlceras genitales y uveítis. Las manifestaciones oculares, neurológicas y vasculares determinan el pronóstico de la enfermedad. Las variadas manifestaciones clínicas y la falta de pruebas diagnósticas hacen de la enfermedad de Behçet un reto diagnóstico. En México se desconoce su prevalencia. Se presenta el caso de una paciente de 10 años de edad, con cuadro faríngeo viral, dolor y úlceras en el área genital; representa un reto diagnóstico ante la ausencia de otros síntomas y porque se trata de una entidad de baja prevalencia y alta heterogeneidad clínica.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Matteson, E.L., “Notes on the history of eponymic idiopathicvasculitis: the diseases of Henoch and Schönlein,Wegener, Churg and Strauss, Horton, Takayasu, Behçet,and Kawasaki”, Arthritis Care Res, 2000, 13 (4): 237-245.

2. Calzada-Hernández, J., “Enfermedad de Behçet”, ProtocDiagn Ter Pediatr, 2020, 2: 201-212.

3. Jennette, J.C., Falk, R.J., Bacon, P.A., Basu, N., Cid, M.C.,Ferrario, F. et al., “2012 revised International Chapel HillConsensus Conference Nomenclature of Vasculitides”,Arthritis Rheum, 2013, 65 (1): 1-11.

4. Ozen, S., Ruperto, N., Dillon, M.J., Bagga, A., Barron,K., Davin, J.C. et al., “eular/pres endorsed consensuscriteria for the classification of childhood vasculitides”,Ann Rheum Dis, 2006, 65 (7): 936-941.

5. Koné-Paut, I., Shahram, F., Darce-Bello, M., Cantarini, L.,Cimaz, R., Gattorno, M. et al., “pedbd Group. Consensusclassification criteria for paediatric Behçet’s diseasefrom a prospective observational cohort: pedbd”, AnnRheum Dis, 2016, 75 (6): 958-964.

6. Bang, D., Lee, J.H., Lee, E.S., Lee, S., Choi, J.S., Kim,Y.K. et al., “Epidemiologic and clinical survey of Behcet’sdisease in Korea: the first multicenter study”, JKorean Med Sci, 2001, 16 (5): 615-618.

7. Karincaoglu, Y., Borlu, M., Toker, S.C., Akman, A., Onder,M., Gunasti, S. et al., “Demographic and clinical propertiesof juvenile-onset Behçet's disease: a controlledmulticenter study”, J Am Acad Dermatol, 2008, 58 (4):579-584.

8. Kaneko, F., Oyama, N. y Nishibu, A., “Streptococcal infectionin the pathogenesis of Behçet’s disease and clinicaleffects of minocycline on the disease symptoms”,Yonsei Med J, 1997, 38 (6): 444-454.

9. Baskan, E.B., Yilmaz, E., Saricaoglu, H., Alkan, G., Ercan,I., Mistik, R., Adim, S.B., Goral, G., Dilek, K. y Tunali, S.,“Detection of parvovirus b19 dna in the lesional skinof patients with Behçet’s disease”, Clin Exp Dermatol,2007, 32 (2): 186-190.

10. Ersoy, O., Ersoy, R., Yayar, O., Demirci, H. y Tatlican, S.,“H pylori infection in patients with Behcet’s disease”,World J Gastroenterol, 2007, 13 (21): 2983-2985.

11. Gündüz, O., “Histopathological evaluation of Behçet’sdisease and identification of new skin lesions”, PathologRes Int, 2012, 2012: 209316.

12. De Menthon, M., Lavalley, M.P., Maldini, C., Guillevin, L.y Mahr, A., “hla-b51/b5 and the risk of Behçet’s disease:a systematic review and meta-analysis of case-controlgenetic association studies”, Arthritis Rheum, 2009, 61(10): 1287-1296.

13. Hatemi, G., Seyahi, E., Fresko, I., Talarico, R., Uçar, D. yHamuryudan, V., “Behçet’s syndrome: one year in review2022”, Clin Exp Rheumatol, 2022, 40: 1461-1471.

14. Koné-Paut, I., “Behçet’s disease in children, an overview”,Pediatr Rheumatol Online J, 2016, 14 (1): 10.

15. Faezi, S.T., Paragomi, P., Shahram, F., Shams, H., Shams-Davatchi, C., Ghodsi, Z. et al., “Clinical features ofBehcet’s disease in patients without oral aphthosis”,Mod Rheumatol, 2014, 24 (4): 637-639.

16. López-García, S., Vizán-Caravaca, J.R. y García-Castro,J.M., “Síndrome de Behçet”, Aten Primaria, 2020, 52(4): 275-276.

17. Ideguchi, H., Suda, A., Takeno, M., Ueda, A., Ohno, S.e Ishigatsubo, Y., “Behçet disease: evolution of clinicalmanifestations”, Medicine (Baltimore), 2011, 90 (2):125-132.

18. International Study Group for Behçet’s Disease, “Criteriafor diagnosis of Behçet’s disease”, Lancet, 1990,335 (8697): 1078-1080.

19. Shahram, F., Assadi, K., Davatchi, F., Nadji, A., Jamshidi,A., Chams, C. y Akbarian, M., “Chronology of clinicalmanifestations in Behçet’s disease. Analysis of 4 024cases”, Adv Exp Med Biol, 2003, 528: 85-89.

20. Davatchi, F., Shahram, F., Chams-Davatchi, C., Shams,H., Nadji, A., Akhlaghi, M. et al., “Behcet’s disease inIran: analysis of 6 500 cases”, Int J Rheum Dis, 2010,13 (4): 367-373.

21. Karincaoglu, Y., Borlu, M., Toker, S.C., Akman, A., Onder,M., Gunasti, S. et al., “Demographic and clinical propertiesof juvenile-onset Behçet’s disease: a controlledmulticenter study”, J Am Acad Dermatol, 2008, 58 (4):579-584.

22. Kalra, S., Silman, A., Akman-Demir, G., Bohlega, S.,Borhani-Haghighi, A., Constantinescu, C.S. et al., “Diagnosisand management of neuro-Behçet’s disease:international consensus recommendations”, J Neurol,2014, 261 (9): 1662-1676.

23. Batu, E.D., “Diagnostic/classification criteria in pediatricBehçet’s disease”, Rheumatol Int, 2019, 39 (1): 37-46.doi: 10.1007/s00296-018-4208-9.

24. Sota, J., Rigante, D., Lopalco, G. et al., “Clinical profileand evolution of patients with juvenile-onset Behçet'ssyndrome over a 25-year period: insights from the aidanetwork”, Intern Emerg Med, 2021, 16 (8): 2163-2171.

25. Yildiz, M., Haslak, F., Adrovic, A., Sahin, S., Koker, O.,Barut, K., Kasapcopur, O., “Pediatric Behçet’s disease”,Front Med (Lausana), 2021, 8: 627192.5.